What Works the Same as Ozempic: Your Guide to Similar Weight Loss Solutions

Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Nothing else is Ozempic — but several FDA-approved medications act on the same receptor, and semaglutide itself, the active ingredient in Ozempic, now appears under four different approved labels. That is the honest answer to "what works the same as Ozempic": the closest matches are other semaglutide products, followed by other GLP-1 receptor agonists, followed by a dual-receptor agonist that works on a second pathway as well. What separates them is not chemistry alone. It is what each one is approved to treat, which is the part most comparison lists leave out.

Start With What Ozempic Is Approved to Do

Per the Ozempic prescribing information (revised 05/2026), Ozempic is a glucagon-like peptide-1 receptor agonist injected once weekly, indicated in adults with type 2 diabetes for glycemic control, for reduction of major adverse cardiovascular events in those with established cardiovascular disease, and for reduction of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in those with chronic kidney disease. There is no weight-management indication in that label.

So "works the same as Ozempic" splits into two different questions depending on why you are asking. If the goal is glycemic control in type 2 diabetes, the comparison set is other diabetes GLP-1 products. If the goal is weight reduction, the comparison set is the products actually approved for weight management — which is a different list, even when the molecule is identical.

The Same Molecule Under Different Labels

Semaglutide is approved in four forms. Ozempic injection covers the three type 2 diabetes indications above. Rybelsus and Ozempic tablets share a single prescribing information (revised 1/2026) covering oral semaglutide for glycemic control in type 2 diabetes and for reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk. Rybelsus tablets come in 3 mg, 7 mg, and 14 mg; Ozempic tablets in 1.5 mg, 4 mg, and 9 mg. The label states plainly that the two are not substitutable on a milligram-to-milligram basis.

Weight management sits with Wegovy (prescribing information revised 06/2026). Wegovy injection is indicated, alongside a reduced-calorie diet and increased physical activity, to reduce major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain that reduction long term in adults and pediatric patients aged 12 and older with obesity and in adults with overweight plus at least one weight-related condition; and, under accelerated approval, for noncirrhotic MASH with moderate to advanced liver fibrosis. Wegovy tablets, at 1.5 mg, 4 mg, 9 mg, and 25 mg, carry the cardiovascular and weight indications in adults but not the pediatric or MASH indications.

Other GLP-1 Receptor Agonists

Liraglutide, marketed as Victoza, is a GLP-1 receptor agonist indicated as an adjunct to diet and exercise for glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes, and to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It is administered daily rather than weekly, which is the practical difference most people notice first.

Head-to-head data exist and are in the Ozempic label itself. In a 56-week open-label trial of 813 patients on background metformin, with or without a sulfonylurea, Ozempic 1 mg reduced HbA1c by 1.4% versus 0.9% for exenatide extended-release 2 mg once weekly, a difference of 0.5% (95% CI −0.7 to −0.3), with mean body weight changes of −4.8 kg and −2.0 kg respectively. Against dulaglutide, the published SUSTAIN 7 trial compared once-weekly semaglutide with once-weekly dulaglutide in type 2 diabetes. Comparative trials like these are why clinicians rarely treat the class as interchangeable.

The label also carries a comparison against insulin, which is often the real-world alternative rather than another GLP-1 product. In a 30-week open-label trial of 1,089 adults on metformin or metformin plus a sulfonylurea, HbA1c fell 1.2% on Ozempic 0.5 mg and 1.5% on Ozempic 1 mg versus 0.9% on insulin glargine, with mean body weight changes of −3.2 kg, −4.7 kg, and +0.9 kg respectively. Weight direction, not just magnitude, is part of why these agents occupy the position they do in diabetes care.

The Dual-Agonist Option

Tirzepatide is not a GLP-1 receptor agonist alone; it is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, and it too carries two brand identities. Mounjaro is approved for glycemic control in type 2 diabetes. Zepbound is approved for chronic weight management and, since December 2024, for moderate to severe obstructive sleep apnea in adults with obesity — the first medication approved for that condition.

In SURPASS-2, a 40-week open-label trial of 1,879 adults with type 2 diabetes, body weight reductions were greater with tirzepatide than with semaglutide 1 mg, with least-squares mean estimated treatment differences of −1.9 kg, −3.6 kg, and −5.5 kg across the three tirzepatide doses studied. In the obesity program, SURMOUNT-1 ran 72 weeks in 2,539 adults with obesity or overweight and reported mean weight changes of −15.0%, −19.5%, and −20.9% versus −3.1% with placebo. For comparison, STEP 1, the semaglutide 2.4 mg obesity trial, ran 68 weeks and reported −14.9% versus −2.4%. Different molecules, different trial designs, different populations — the numbers are not directly interchangeable.

Oral Small Molecules Are a Newer Category

Orforglipron, marketed as Foundayo, was approved on April 1, 2026. It is a small-molecule GLP-1 receptor agonist rather than a peptide, which is what allows it to be formulated as a conventional tablet without the absorption enhancer that oral semaglutide requires. That difference shows up in the labeling: the oral semaglutide label specifies administration on an empty stomach in the morning with no more than four ounces of water, tablets swallowed whole, and a wait of at least 30 minutes before food, other beverages, or other oral medications. Your pharmacy label and your prescriber govern how any of this applies to you.

There is, importantly, no FDA-approved oral tirzepatide and no oral Zepbound. Any product marketed under those descriptions is not an approved finished product, whatever the marketing says.

What "Works the Same" Does Not Mean

Sharing a receptor target does not make two drugs interchangeable at the pharmacy counter. None of these products has an approved generic, so a compounded preparation is not a generic version of any of them — compounded semaglutide and tirzepatide are not FDA-approved finished products, and the agency does not review them for safety, effectiveness, or quality before marketing. Retatrutide, which appears constantly in these comparisons online, remains investigational.

Insurance coverage tends to follow the approved indication rather than the molecule, which is why a plan may cover one tirzepatide product and refuse the other for the same person. Choosing among these options is a prescriber's decision built on your diagnoses, your other medications, your history, and what your coverage will actually support.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

What works the same as Ozempic?

The closest matches are other semaglutide products: Rybelsus and Ozempic tablets share one prescribing information for type 2 diabetes, and Wegovy holds the weight-management and cardiovascular indications. Beyond semaglutide, other GLP-1 receptor agonists such as liraglutide and dulaglutide act on the same receptor, and tirzepatide adds a second receptor target. None of them is interchangeable with Ozempic.

Is there an Ozempic pill?

Yes. The current prescribing information covers both Rybelsus tablets, at 3 mg, 7 mg, and 14 mg, and Ozempic tablets, at 1.5 mg, 4 mg, and 9 mg, for glycemic control in type 2 diabetes and for reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk. The label states the two products are not substitutable on a milligram-to-milligram basis.

Is Mounjaro or Zepbound the same as Ozempic?

No. Both contain tirzepatide, a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, rather than semaglutide. Mounjaro is approved for glycemic control in type 2 diabetes. Zepbound is approved for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity. Ozempic is approved only for adults with type 2 diabetes.

Which produced more weight loss in trials, semaglutide or tirzepatide?

They were studied in different programs, so direct comparison is limited. SURMOUNT-1 ran 72 weeks in 2,539 adults with obesity or overweight and reported mean weight changes of −15.0%, −19.5%, and −20.9% versus −3.1% with placebo. STEP 1 ran 68 weeks and reported −14.9% versus −2.4%. In SURPASS-2, a diabetes trial, tirzepatide produced greater weight reduction than semaglutide 1 mg.

Is compounded semaglutide a generic version of Ozempic?

No. Ozempic has no approved generic, so nothing compounded can be a generic version of it. Compounded semaglutide is not an FDA-approved finished product, and the agency does not review compounded drugs for safety, effectiveness, or quality before they are marketed. Legitimate compounding is patient-specific preparation by a licensed pharmacy against an individual prescription.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.